Wattana Karnpaet Valuation

Q: What is the Fair Price of NEW-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

NEW-R (THB70) is trading below our estimate of [[fair value]] (THB135.89)

Is NEW-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NEW-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NEW-R (THB70) is trading below our estimate of fair value (THB135.89)

Significantly Below Fair Value: NEW-R is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NEW-R?

Key metric: As NEW-R is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NEW-R. This is calculated by dividing NEW-R's market cap by their current earnings.
What is NEW-R's PE Ratio?
PE Ratio	13.9x
Earnings	฿50.45m
Market Cap	฿700.00m

NEW-R key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	6.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NEW-R's PE Ratio compare to its peers?

The above table shows the PE ratio for NEW-R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.8x
KDH Thonburi Medical Centre	13.5x	n/a	฿1.9b
AHC Aikchol Hospital	14x	n/a	฿2.4b
TRP Aesthetic Connect	21.4x	22.1%	฿3.2b
LPH Ladprao General Hospital	50.4x	n/a	฿3.2b
NEW-R Wattana Karnpaet	13.9x	n/a	฿700.0m

Price-To-Earnings vs Peers: NEW-R is good value based on its Price-To-Earnings Ratio (13.9x) compared to the peer average (24.8x).

Price to Earnings Ratio vs Industry

How does NEW-R's PE Ratio compare vs other companies in the TH Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NEW-R is good value based on its Price-To-Earnings Ratio (13.9x) compared to the TH Healthcare industry average (22x).

Price to Earnings Ratio vs Fair Ratio

What is NEW-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NEW-R PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NEW-R's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Safe Fertility Group

฿3.4b

Provides fertility medical center services in Thailand.

SAFE-R

฿11.30

-16.9%

-38.9%

Wattana Karnpaet

฿700.0m

Engages in the hospital and medical trading businesses in Thailand.

NEW

฿70.00

9.4%

n/a

E for L Aim

฿1.1b

Engages in the distribution of medical devices and equipment in Thailand.

EFORL-R

฿0.27

12.5%